TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean 24 hour faecal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of breast cancer (BC) diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: CAR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VPT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcomes post-midclavicular fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SPADI score indicating pain and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sick-leave status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Overall satisfaction with the test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interference with overall daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chest discomfort during the pH test
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of difficult delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Patient satisfaction with insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CSF concentration of flurbiprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSF/plasma drug concentration ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine phosphate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality due to multiple organ dysfunction syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Peak plasma concentration of GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half life of acylated ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Marksmanship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold target identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting and 2 h glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: macrovascular and microvascular benefits of lipid lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of intra-treatment episodes of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscular cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac arrhythmia hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemic stroke hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: congestive heart failure hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemic heart disease hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: persistence with denosumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to rectal distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of language delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B cell-related malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: drug efficacy recall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NEFA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LnRHI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of responders under the CLBP RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement criteria on the PGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding during spine surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hypotension during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean increase in IOP six hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean IOP change twenty to twenty-four hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Liver signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving HbA1c <7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time for vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of redirections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: successful TOV within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration in static single-leg stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteroposterior body sway in perturbed single-leg stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance lunged
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number and severity of difficulties experienced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of large adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pain score on arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score at 1 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postnatal care utilization
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: weight z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBCL score at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of referrals by child health professionals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parental preparedness for well-child visit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduced risk of migraine with aura
Endpoint domain: Mortality/survival
Primary endpoint: maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental peak power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state oxygen consumption at 60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inadvertent vessel puncture frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Mean circulating ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean circulating GGT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incident liver disease
Endpoint domain: Mortality/survival
Primary endpoint: Filter dose captured at the exit of the VHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak inspiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hand-Foot Syndrome (HFS)
Endpoint domain: Adverse events/effects
Primary endpoint: Skin-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General health-related quality of life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Finger-floor distance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Straight leg raise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Popliteal angle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of integrin subunit RNA encoding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binding and neutralizing anti-Ebola virus glycoprotein antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: injection site pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction on the MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved full remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in state anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in WDEQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of increases in EPDS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alleviation of pain during SWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition (CST‐14)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognition (CST‐20)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Positive group behaviour (SIPO)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mortality associated with HbA1c levels
Endpoint domain: Mortality/survival
Primary endpoint: Mean methionine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum concentration of BFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of TFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of bimatoprost amide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean logMAR change from baseline in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insertion conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apnea times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cage subsidence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: effectiveness of anaesthetics with vasoconstrictors in perineal laceration repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective changes in arousal and lubrication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deeper CCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual salivary fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADOS severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMDS Social domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VABS Communication and Social domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS ≤3 in the early postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate PTPS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe PTPS
Endpoint domain: Adverse events/effects
Primary endpoint: Duodenal ulcer healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of proximal lower-limb deep-vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Death from any cause at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: urinary/bowel dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' ability to correctly identify herbal tinctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Alcohol Concentration (BrAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep stages changes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wake increase
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Genital HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: active choroidal neovascularization exudation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in verbal aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: false positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in muscle mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood pressure goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in IL‐1RA per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Declarative memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Questionnaire (ACQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma Quality of Life Questionnaire (AQLQ) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to return to play
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of new vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: Seven-year decreases in total hip bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision increasing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean mitral valve area difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: direct-total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: mean number of trabecular cells per field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total lean mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically elevated components of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mental Health Related Quality of Life (MHRQL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral health hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: glutamate to creatine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median pain reduction at 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change in pain intensity at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced area under the plasma MTX concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clearance of MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytological cellularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: malnutrition etiology investigation by physicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: management by a dietitian
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of febrile episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of probable infection
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization for treatment of infection
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Optimal wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total operating room time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: NSE concentration at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant short-term safety signals
Endpoint domain: Adverse events/effects
Primary endpoint: HIS values for CFS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete emulsification of the lens nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median compliance with CONSORT criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median fraction of correct implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Remission rate at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CDAI change at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for activity index in LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for chronicity index in LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vital load per liver cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ISI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PSQI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual improvement at 6 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean amount of improvement in M-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean degree of asymmetric elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of heartburn improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery from acute illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean body weight gain during recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean episodes of diarrhoea during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lipodystrophy diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LD severity grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of cortisone
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in visits to the surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of worsening renal function (WRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in HbA(1c) from baseline at week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with HbA(1c) <7% at week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of breastfeeding at six months
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: self-efficacy to manage diabetes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: micro-push-out bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: treatment duration for alleviating initial crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression-free interval
Endpoint domain: Mortality/survival
Primary endpoint: mean retention strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of laboratory tests performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use